The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 25, 2022
Filed:
Nov. 14, 2018
Institut Régional Du Cancer DE Montpellier (Icm), Montpellier, FR;
Institut National DE LA Santé ET DE LA Recherche Médicale (Inserm), Paris, FR;
Université DE Montpellier, Montpellier, FR;
Céline Gongora, Montpellier, FR;
Diego Tosi, Montpellier, FR;
INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM), Montpellier, FR;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris, FR;
UNIVERSITE DE MONTPELLIER, Montpellier, FR;
Abstract
The invention concerns a pharmaceutical combination of an inhibitor of the androgen receptor signaling pathway and of a p38 inhibitor for use in the treatment of prostate cancer in individuals wherein the prostate tumor cells express the AR-V7 variant androgen receptor protein or for preventing the occurrence of resistance in patients suffering from prostate cancer treated by an inhibitor of the androgen receptor signaling pathway. The invention further concerns a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient. The invention also concerns the use of a p38 inhibitor for restoring the sensitivity to androgen-deprivation therapy (ADT) in patients suffering from prostate cancers having acquired a resistance to ADT following a treatment with an inhibitor of the androgen receptor signaling pathway and wherein the prostate tumour cells express the AR-V7 variant androgen receptor protein.